A5084369827- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Cancer Research and Treatments
- Venous Thromboembolism Diagnosis and Management
- Chemotherapy-induced cardiotoxicity and mitigation
- COVID-19 Clinical Research Studies
- Ovarian cancer diagnosis and treatment
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- PARP inhibition in cancer therapy
- Takotsubo Cardiomyopathy and Associated Phenomena
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Multiple and Secondary Primary Cancers
- Central Venous Catheters and Hemodialysis
Azienda Sanitaria Unità Locale di Reggio Emilia
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
Azienda Ospedaliera S.Maria
2017
Hospital Oncológico Andrés Grillasca
2015
Highlights•The oral factor Xa inhibitors are effective and safe in VTE treatment.•Cancer patients, especially during active treatment may develop VTE.•A low rate of AEs edoxaban related with an impact on antineoplastic therapy was observed.•More than the half occurred first 30 days.•Edoxaban-related did not result a lower overall QoL patients.AbstractBackgroundThe inhibitor, edoxaban, is cancer-associated Venous Thromboembolism (VTE) treatment. The EDOI study aims to evaluate compliance...
The NIVACOR trial is a phase II study assessing the efficacy and safety of nivolumab in combination with FOLFOXIRI/bevacizumab first-line setting patients affected by metastatic colorectal cancer (mCRC) RAS/BRAF mutated. We report run-in results first 10 enrolled. Patients received triplet chemotherapy FOLFOXIRI scheme plus bevacizumab, association every 2 weeks for 8 cycles (induction phase) followed bevacizumab (maintenance phase), until progression disease or unacceptable toxicities. ten...
In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status; therefore, data on must available in order consider most adequate strategy of care. We carried out cohort study risk hospitalization for COVID-19, oncological history, and outcomes COVID-19 infected admitted Hospital Reggio Emilia. Between 1 February 3 April 2020, total 1226 were hospitalized. The number hospitalized with infection was 138 (11.3%). median age...
e14156 Background: Checkpoint inhibitors in cancer therapy have shown survival benefits the treatment of several ATs. However, risk serious side effects seems greater certain types tumors presenting reduced compliance with therapy. The aim this study is to evaluate safety profile and clinical IT, as appraised using clinically related biomarkers pts outside trials. Methods: In retrospective study, data were evaluated on Reggio Emilia Provincial Oncology Network who treated for ATs Nivolumab,...
3046 Background: In mCRC patients RAS/BRAF testing is usually performed on tissue biopsy in order to select for treatment with anti-EGFR monoclonal antibodies. Several studies described discordant RAS status between and cfDNA from the same patients. addition, up 30% of secondary resistance therapies become mutant at progression. The LIBImAb study a phase III, randomized, open-label, comparative, multi-centre trial assess superiority terms efficacy bevacizumab versus cetuximab combination...
Capecitabine has demonstrated significant activity in metastatic breast and colorectal cancer. During the course of treatment with capecitabine, we observed that a relevant number patients developed elevated levels mean corpuscular volume (MCV) red blood cells.This retrospective analysis reviewed capecitabine 35 histologically proven advanced colon After 9 weeks treatment, restaging was performed using criteria proposed by Committee Response Evaluation Criteria Solid Tumours.Prior to first...
4056 Background: REGO is an oral multi-targeted TKI that showed promising activity in advanced HER2-neg gastric cancer pts. The a-MANTRA study aimed to evaluate the efficacy and safety of as maintenance after first-line (1L) therapy GC/GEJ tumors. Methods: This a randomized, double-blind, placebo-controlled, multicenter Phase-II which HER2 neg pts with disease control 1L platinum fluoropyrimidines-based therapy, were randomized (1:1 ratio) receive placebo (ARM A) or B) starting at 80 mg...
TPS8591 Background: Surgery for malignant pleural mesothelioma (MPM) is indicated mainly in multimodal approaches and clinical trial settings. Different studies have shown significantly lower complication rates, peri-operative morbidity mortality with pleural/decortication (P/D), similar overall survival rates. The biology of shows significant heterogeneity. Surgical tumor reduction may create a host environment more amenable to immunotherapy by reducing the ratio cells versus antitumor...
TPS3636 Background: KRAS, NRAS, and BRAF mutations are well-established negative predictive biomarkers of response to anti-EGFR monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC) patients (pts). In clinical practice, RAS/BRAF wild-type (wt) receive first-line therapy regimens containing agents. However, tumor heterogeneity might drive primary acquired resistance MoAbs. fact, circulating DNA (ctDNA) testing reveals approximately 10% pts who resulted wt at tissue. addition,...
Biliary tract cancers (BTCs) are a pool of diseases with poor prognosis and there is no orphan drug available. Currently, molecular targets have been tested as druggable oncogenic drivers. C‑ros oncogene 1 (<em>ROS1</em>) rearrangements previously described in various tumors, including BTCs; however, data regarding their incidence biological significance controversial. Therefore, retrospective multicenter study was performed to assess the <em>ROS1</em> BTCs by means immunohistochemistry...
6564 Background: The EDOI Study (EUDRACT 2018-003833-14) was designed to evaluate venous thromboembolism (VTE), a common complication of cancer and therapy. VTE contributes mortality morbidity, may interfere with When drafting the protocol, standard treatment for consisted low-molecular weight heparin followed by vitamin K antagonists. DOACs are as effective antagonists in VTE. Edoxaban has been confirmed be safe Adverse events (AEs) associated can delay or chemotherapy; date, data regarding...
e15590 Background: mCRC patients (pts) have a median survival of 13-24 months with 5-year rate about 1%. LTSs are defined as pts greater than or equal to 36 after diagnosis mCRC. Mutational status, new treatments, and surgery resection advances led improved outcomes. Methods: This is single-center retrospective analysis 106 consecutive CRC synchronous metachronous metastases diagnosed from the AUSL-IRCCS Reggio Emilia Comprehensive Cancer Center between January 1 st , 2017, November 30,...